131 related articles for article (PubMed ID: 11995358)
1. Azathioprine side effects in the treatment of chronic inflammatory bowel disease.
González Lara V; Pérez Calle JL
Rev Esp Enferm Dig; 2001 Dec; 93(12):765-8. PubMed ID: 11995358
[No Abstract] [Full Text] [Related]
2. Azathioprine in inflammatory bowel disease, a safe alternative?
Tanis AA
Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598
[TBL] [Abstract][Full Text] [Related]
3. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.
van Dieren JM; van Vuuren AJ; Kusters JG; Nieuwenhuis EE; Kuipers EJ; van der Woude CJ
Gut; 2005 Nov; 54(11):1664. PubMed ID: 16227370
[No Abstract] [Full Text] [Related]
4. Patients with inflammatory bowel disease: their response to information leaflets about medical therapy in particular azathioprine.
Ward B; Shah S; Eaden JA; Mayberry JF
Arq Gastroenterol; 1998; 35(4):264-6. PubMed ID: 10347709
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
[No Abstract] [Full Text] [Related]
6. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Su C; Lichtenstein GR
Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab M; Herrlinger K; Schaeffeler E; Stange EF
Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
[No Abstract] [Full Text] [Related]
9. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
Rogler G
Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
[No Abstract] [Full Text] [Related]
10. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
11. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study.
Al Rifai A; Prasad N; Shuttleworth E; McBurney H; Pushpakom S; Robinson A; Newman W; Campbell S
Eur J Gastroenterol Hepatol; 2011 Feb; 23(2):153-8. PubMed ID: 21164349
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
Corominas H; Díaz C; Vázquez G; Baiget M
Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
[No Abstract] [Full Text] [Related]
13. Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease.
de Fonclare AL; Khosrotehrani K; Aractingi S; Duriez P; Cosnes J; Beaugerie L
Arch Dermatol; 2007 Jun; 143(6):744-8. PubMed ID: 17576940
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
Atreya I; Neurath MF
Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
[TBL] [Abstract][Full Text] [Related]
15. Position statement: immunomodulator therapy for inflammatory Bowel disease.
Lavy A; Chowers Y; Odes HS; Eliakim R;
Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
[No Abstract] [Full Text] [Related]
16. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
19. Review article: monitoring of immunomodulators in inflammatory bowel disease.
Aberra FN; Lichtenstein GR
Aliment Pharmacol Ther; 2005 Feb; 21(4):307-19. PubMed ID: 15709982
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
